Biomea Fusion, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
SAN CARLOS, Calif., May 12, 2026 -- Biomea Fusion, Inc. , a clinical-stage diabetes and obesity company, today announced that management will participate in the following investor conferences: ...
Biomea Fusion Q1 2026 beat estimates with a smaller-than-expected loss, driven by cost cuts. Pipeline progress includes obesity and diabetes data readouts expected in Q2 and Q4 2026.
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.24) by 29.17 percent. This is a 78.75 percent increase over losses of $(0.80) per share from the
Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to...
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights May 5, 2026 2:30 PM EDTCompany...
Presenter SpeechMichael King All right. Good afternoon, everybody. Thank you for joining us this afternoon for what I believe will be an informative and lively discussion with our guest KOL, Dr.
SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans. The presentations include data from icovamenib, the Company’s investigational oral menin inhibitor
Rodman & Renshaw Director of Research Michael King hosted an endocrinology-focused discussion with Dr. Alexander Abitbol, an endocrinologist and assistant medical director at LMC Healthcare, ahead of the American Diabetes Association (ADA) meeting in New Orleans. The conversation centered on tre
Rodman & Renshaw Director of Research Michael King hosted an endocrinology-focused discussion with Dr. Alexander Abitbol, an endocrinologist and assistant medical director at LMC Healthcare, ahead of the American Diabetes Association (ADA) meeting in New Orleans. The conversation centered on tre
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Citations for AMAT, BMEA, ACRS, KALU, SION.
Citizens analyst Jonathan Wolleben initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Market Outperform rating and announces Price Target of $9.
Biomea Fusion (NASDAQ:BMEA) executives highlighted early, exploratory clinical data for icovamenib in type 1 diabetes, presenting top-line results from the company’s COVALENT-112 proof-of-concept study focused on safety, tolerability, and signals of beta cell function. Management said the results ma
Biomea Fusion (NASDAQ:BMEA) executives highlighted early, exploratory clinical data for icovamenib in type 1 diabetes, presenting top-line results from the company’s COVALENT-112 proof-of-concept study focused on safety, tolerability, and signals of beta cell function. Management said the results ma
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes April 28, 2026 8:30 AM EDTCompany...
Icovamenib in Type 1 Diabetes COVALENT-112 Topline Results BIOMEA FUSION CONFERENCE CALL 28 APRIL 2026 Table of...
A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence observed through Week 52, with mean C-peptide AUC largely preserved in 200 mg group (~7% decline from baseline) following only 12 weeks of dosingPreservation of C-peptide also observed in patients diagnosed between 3-15 years (n=9)Icovamenib was generally well tolerated across all dosing arms and dem
A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence observed through Week
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline 26-week primary endpoint data from both Phase II studies anticipated 4Q 2026 SAN CARLOS, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the first p
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 8.81M | $13.48M | 0.00% | Unchanged | 2026-03-31 |
| RenTech | quant | 1.31M | $2.01M | 0.00% | Added+174.3% | 2026-03-31 |
| TwoSigma | quant | 388.7K | $594.71K | 0.00% | Trimmed-8.2% | 2026-03-31 |
| StateStreet | passive | 208.0K | $318.26K | 0.00% | Added+26.0% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | -0.21 | — | — |
| 2026-05-11 | -0.19 | -0.17 | +10.30% |
| 2026-03-24 | -0.22 | -0.12 | +45.62% |
| 2025-11-04 | -0.29 | -0.24 | +17.55% |
| 2025-08-05 | -0.51 | -0.51 | +0.59% |
| 2025-05-05 | -0.60 | -0.80 | -33.09% |
| 2025-03-31 | -0.93 | -0.81 | +12.85% |
| 2024-10-29 | -0.91 | -0.91 | -0.39% |
| 2024-07-31 | -1.09 | -1.03 | +5.27% |
| 2024-05-02 | -0.93 | -1.09 | -16.58% |
| 2024-03-28 | -0.88 | -0.98 | -11.31% |
| 2023-10-30 | -0.83 | -0.80 | +3.14% |
| 2023-07-31 | -0.88 | -0.70 | +20.72% |
| 2023-05-02 | -0.81 | -0.98 | -20.88% |
| 2023-03-28 | -0.61 | -0.86 | -41.86% |
| 2022-11-07 | -0.64 | -0.78 | -21.03% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BMEA | +0.73% | +3.76% | +11.29% | -4.17% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -2.24% | +8.40% | +14.73% | -16.86% |